Qure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ETLEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company ...

Q2 2025 Management View CEO Matthew Kapusta highlighted that "the first half of 2025 has been tremendously productive for the company as we advance AMT-130 towards potentially becoming the first ...

Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 top ...

Investing.com - uniQure N.V. (NASDAQ: QURE) reported second quarter revenue that fell short of analyst expectations, though its loss per share was narrower than anticipated. The gene therapy company’s ...

Qure (NASDAQ:QURE) is one of the biotech stocks to buy according to Wall Street analysts. Earlier on June 2, uniQure provided a regulatory update on AMT-130, which is the company’s investigational ...

AMSTERDAM (AP) — AMSTERDAM (AP) — UniQure NV (QURE) on Tuesday reported a loss of $37.7 million in its second quarter. On a per-share basis, the Amsterdam-based company said it had a loss of 69 cents.

--uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced promising interim data, including up to 24 months of ...

uniQure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges despite strong clinical data.

With the value for uniQure close to $33/share, it represents a very attractive bargain, trading at below $6 recently. Find out why QURE stock is a Strong Buy.

The uniQure gene therapy is being tested in an open-label Phase 3 study that dosed 54 patients, each of them given a single infusion. The main goal was to measure FIX levels at 26 weeks.

The stock price of uniQure (NASDAQ:QURE), a gene therapy company, has seen a rise of 20% in a week, while it is up 10% over the last month. The recent rise can be attributed to its Q3 loss of $0. ...

The stock price of uniQure, a gene therapy company, has seen a rise of 20% in a week, while it is up 10% over the last month. The recent rise can be attributed to its Q3 loss of $0.79 per share ...